课题基金 / 基金详情

Understanding and Predicting Loss to Follow-up from Multi-Drug Resistant Tuberculosis Treatment in the Setting of High-HIV Burden

Understanding and Predicting Loss to Follow-up from Multi-Drug Resistant Tuberculosis Treatment in the Setting of High-HIV Burden
了解和预测高艾滋病毒负担背景下耐多药结核病治疗的随访损失
批准号:
10326602
负责人:
Katherine C McNabb
金额:
$5.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2025-08-31

项目摘要

项目成果

Katherine C McNabb的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Globally, Tuberculosis (TB) is one of the leading infectious causes of death and a particular concern in countries with a high HIV burden. With only 57% of cases being successfully treated, multi-drug resistant-TB (MDR-TB) has become a substantial barrier to TB control. High rates of loss to follow up (LTFU) (i.e., missing two or more consecutive months of treatment) are a major contributor to the low MDR-TB treatment success rates. LTFU may lead to additional antibiotic resistance, MDR-TB treatment failure, and death. The World Health Organization recommends that patients at-risk for LTFU be given priority attention, but there is currently no evidence-based way to identify these patients. In order to address this gap, the proposed study will develop a prediction model for LTFU from MDR-TB treatment based on characteristics present at treatment initiation. If accurate, this model will identify the patients who are at high-risk for LTFU and who will draw the greatest benefit from interventions that promote care engagement and retention. Although the reasons for LTFU are complex, past research has yielded a number of potential predictors that will inform the proposed prediction model, including male sex, age, housing instability, alcohol use, substance use, employment status, education level, rural residence, and prior episode(s) of TB. In addition to factors present at treatment initiation, the relationship between LTFU and factors that change throughout treatment, including adverse treatment events and treatment regimen, will be examined to develop a broader understanding of MDR-TB care engagement. The proposed study will be nested within the control arm of a cluster-randomized trial of MDR-TB patients in South Africa (R01 AI104488). The specific aims of the proposed study, titled “Understanding and Predicting Loss to Follow-up from MDR-TB Treatment in the Setting of High-HIV Burden”, are to conduct a nested, retrospective cohort study among patients who were LTFU or successfully completed MDR-TB treatment (i.e., cured or completed treatment) to: (1a) develop a prediction model for LTFU from MDR-TB care based on the patient characteristics available at treatment initiation utilizing LASSO regression and k-fold cross-validation; (1b) adapt the prediction model developed in Aim 1a into a tool that can be used by providers at the point of care to estimate a patient’s risk for LTFU; (1c) determine if type of treatment regimen is a risk factor for LTFU and if it improves the fit of the prediction model developed in Aim 1a; and (2) examine the relationship between LTFU and the timing and burden of adverse treatment effects. This study will be the first to take a predictive modeling approach to guide MDR-TB providers in identifying patients at high-risk for LTFU and prioritizing their receipt of support services in order to ultimately improve MDR-TB treatment outcomes in resource-limited settings. Through the proposed study and training plan, the applicant will gain experience analyzing large, complex longitudinal data and applying machine learning to optimize patient engagement and clinical care.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding and Predicting Loss to Follow-up from Multi-Drug Resistant Tuberculosis Treatment in the Setting of High-HIV Burden
  • 批准号:
    10676317
  • 项目类别:
  • 资助金额:
    $5.27万
  • 财政年份:
    2021
  • 负责人:
    Katherine C McNabb
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: